Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Bluegreen who wrote (16408)	11/6/2003 7:23:31 AM
From: Robert K.	Respond to of 17367

Am well aware of agressiveness of SPOC. IMO this shows the marketing know-how and is a hint of the marketing blitzkreig to come shortly. IMO we aint seen nuthin yet. Regarding medline>am impressed by your finds lately in the respect that you found them before me. IMO that gives me a hint of your appetite for all things bpi and also xoma. Also they never did a p3 liver, but the writeup on p2 was very good. I read the paper before it went pay per view. Great writeup. Regarding italians> about time they got on board. BPI has been thought to play "perhaps" important role in RA, so Psa is no surprise to me. Keep up them posts. keep the faith. Got the number I needed fyi.